证 券 研 究 报 告 英伟达（NVDA）FY26Q3 业绩点评及业绩说明会纪要 业绩与指引双双超预期，GB300+Rubin 系列 5000 亿美金在手订单清晰可见 ❖ 事项： 2025 年 11 月 20 日 NVIDIA 发布 FY26Q3 报告，FY26Q3 截止至 2025 年 10 月 26 日，并召开业绩说明会。 ❖ 评论： 1.业绩情况：FY26Q3 营收 570 亿美元，同比增长 62%，环比增长 22%。GAAP 毛利率为 73.4%，Non-GAAP 毛利率为 73.6%。Non-GAAP EPS 为 1.30 美元， 盈利表现强劲。研发支出 47.1 亿美元，同比增长 39%。 2.营收划分：（1）数据中心业务：FY26Q3 数据中心营收 512 亿美元，同比增 长 66%，环比增长 25%，占总营收 90%以上，其中计算业务营收 430 亿美元 （YoY+56%），网络业务营收 81.9 亿美元（YoY+162%）。（2）游戏业务：FY26Q3 游戏业务营收 43 亿美元，同比增长 30%，受益于 Blackwell 架构在消费级显 卡的渗透。（3）专业可视化业务：营收 7.6 亿美 ...

证 券 研 究 报 告 尚品宅配（300616）2025 年三季报点评 强推（维持） Q3 业绩扭亏为盈，期间费用率收窄 目标价：17.9 元 事项： ❖ 公司公布 2025 年三季报。前三季度，公司实现营业收入/归母净利润/扣非归母 净利润 25.5/-0.79/-0.91 亿元，同比-6.7%/亏损收窄/亏损收窄。25Q3，公司实现 营业收入/归母净利润/扣非归母净利润 10.0/0.01/-0.03 亿元，同比-2.3%/扭亏为 盈/亏损收窄。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 3,789 | 3,583 | 3,689 | 3,849 | | 同比增速(%) | -22.7% | -5.4% | 3.0% | 4.4% | | 归母净利润(百万) | -215 | -43 | 62 | 107 | | 同比增速(%) | -432.1% | 79.9% | 243.8% | 72.5% | | 每股盈利(元 ...

证券分析师：徐康 电话：021-20572556 邮箱：xukang@hcyjs.com 执业编号：S0360518060005 行业研究 证 券 研 究 报 告 金融资金面跟踪：量化周报（2025/11/10~2025/11/14） 推荐（维持） 私募超额持续正增，小微盘超额有所走强 | 华创证券研究所 | | --- | 证券分析师：刘潇伟 邮箱：liuxiaowei@hcyjs.com 执业编号：S0360525020001 联系人：杜婉桢 邮箱：duwanzhen@hcyjs.com 本周样本量化私募收益及超额如下：1）300 增强策略周/月/年初以来平均收益分别 为-0.1%/+2.2%/+28.5%，周/月/年初以来平均超额分别为+0.9%/+1.8%/+7.7%；2）500 增 强策略周/月/年初以来平均收益分别为 0%/+1.6%/+38.5%，周/月/年初以来平均超额分别 为 +1.2%/+3.8%/+13.1% ； 3 ） A500 增强策略周 / 月 / 年 初 以 来 平 均 收 益 分 别 为 +0%/+2.6%/+29.9%，周/月/年初以来平均超额分别为+1%/+2.7%/+9. ...

Investment Rating - The report adjusts the investment rating to "Recommended" for the company, indicating an expected outperformance of 10%-20% relative to the benchmark index over the next six months [9][20]. Core Insights - The company reported a 23% year-on-year growth in non-recurring net profit for Q3, indicating a potential for new product launches to drive future growth [2][9]. - Despite a decline in revenue for the first three quarters of 2025, the company achieved a slight increase in net profit for Q3, suggesting an improving trend in profitability [2][9]. - The company’s core product received authoritative recognition, and new products are being launched, which are expected to contribute to future growth [9]. - The company has successfully expanded its overseas business, with foreign revenue increasing by 14.76% year-on-year, now accounting for 20.24% of total revenue [9]. Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 285 million yuan, a decrease of 8.43% year-on-year, and a net profit of 33 million yuan, down 7.26% year-on-year [2]. - The Q3 revenue was 93 million yuan, down 4.22% year-on-year, while the net profit for Q3 was 11 million yuan, up 1.76% year-on-year [2]. - The company’s gross margin for the first three quarters of 2025 was 45.80%, an increase of 0.94 percentage points year-on-year [9]. Future Projections - The company is expected to see net profits of 43 million yuan, 54 million yuan, and 66 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 10.8%, 24.8%, and 21.6% [9]. - The target price for the company is set at 40.1 yuan, reflecting a 13% upside from the current price of 35.48 yuan [4][9].

证 券 研 究 报 告 稳健医疗（300888）2025 年三季报点评 强推（维持） 双轮驱动高质增长，医疗消费齐头并进 目标价：51.4 元 事项： ❖ 公司公布 2025 年三季报。前三季度，公司实现营收/归母净利润/扣非归母净利 润 79.0/7.3/6.8 亿元，YoY+30.1%/+32.4%/+43.9%；25Q3，公司实现营收/归母 净利润/扣非归母净利润 26.0/2.4/2.2 亿元，YoY+27.7%/+42.1%/+50.8%。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 8,978 | 11,333 | 13,096 | 14,753 | | 同比增速(%) | 9.7% | 26.2% | 15.6% | 12.7% | | 归母净利润(百万) | 695 | 997 | 1,201 | 1,412 | | 同比增速(%) | 19.8% | 43.4% | 20.4% | 17.6% | | 每股 ...

事项： 证 券 研 究 报 告 曲美家居（603818）2025 年三季报点评 强推（维持） Q3 业绩符合预期，债务置换与新业务打开想 象空间 ❖ 公司发布 2025 年三季报。前三季度，公司实现营业收入/归母净利润/扣非归母 净利润 25.5/-0.67/-1.11 亿元，同比-3.1%/亏损收窄/亏损收窄。25Q3，公司实现 营业收入/归母净利润/扣非归母净利润 8.23/-0.20/-0.34 亿元，同比-1.4%/亏损 收窄/亏损扩大。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 3,552 | 3,449 | 3,692 | 3,888 | | 同比增速(%) | -11.8% | -2.9% | 7.1% | 5.3% | | 归母净利润(百万) | -163 | -29 | 116 | 227 | | 同比增速(%) | 46.5% | 82.1% | 497.7% | 95.4% | | 每股盈利(元) | ...

证 券 研 究 报 告 事项： ❖ 公司发布 25 年三季报，25Q1-3，营业收入 31.27 亿元（-7.48%），归母净利润 8.60 亿元（-10.11%），扣非净利润 8.15 亿元（-12.36%）。25Q3，营业收入 10.67 亿元（-9.04%），归母净利润 2.89 亿元(-14.30%)，扣非净利润 2.69 亿元(- 18.82%)。 评论： [主要财务指标 ReportFinancialIndex] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,471 | 4,235 | 4,675 | 5,386 | | 同比增速(%) | 0.6% | -5.3% | 10.4% | 15.2% | | 归母净利润(百万) | 1,194 | 1,177 | 1,370 | 1,590 | | 同比增速(%) | -1.9% | -1.5% | 16.4% | 16.1% | | 每股盈利(元) | 2.09 | 2.06 | 2.40 | 2.78 | | 市盈率(倍) | ...

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 50.2 yuan [2][8]. Core Insights - The company reported a total revenue of 3.67 billion yuan for the first three quarters of 2025, a year-on-year decrease of 34.59%. However, the net profit attributable to shareholders increased by 167.73% to 2.152 billion yuan, and the net profit excluding non-recurring items rose by 6.7% to 818 million yuan [2][4]. - The decline in revenue is attributed to changes in the scope of consolidation, as the data from Tianjin Zhongxin Pharmaceutical Co., Ltd. is no longer included this year [2]. - The company’s core products are expected to see significant growth, particularly in the industrial sector, with notable sales increases in key products [8]. Financial Performance Summary - For Q3 2025, the company achieved a single-quarter revenue of 1.019 billion yuan, down 38.08% year-on-year, while the net profit for the quarter was 225 million yuan, up 53.66% year-on-year [2]. - The gross profit margin for Q3 2025 was reported at 75.8%, an increase of 29.2 percentage points year-on-year, and the net profit margin was 21.9%, up 13.3 percentage points year-on-year [8]. - The company’s sales expense ratio increased to 38.6%, while the management expense ratio was 8.3% and the R&D expense ratio was 2.9% [8]. Future Earnings Projections - The report forecasts the company's earnings for 2025 to be 2.24 billion yuan, with subsequent projections of 1.11 billion yuan for 2026 and 1.20 billion yuan for 2027, reflecting a year-on-year growth of 0.5%, a decline of 50.7%, and an increase of 8.8% respectively [8][9]. - The estimated earnings per share (EPS) for 2025 is projected at 2.91 yuan, with a P/E ratio of 16 times [4][9]. Dividend Policy - The company announced a dividend plan for the first three quarters of 2025, proposing a cash dividend of 24.50 yuan per 10 shares (before tax), totaling 1.887 billion yuan, with a payout ratio of 87.67% [8].

证 券 研 究 报 告 公司发布 25 年三季报。25Q1-3，营业收入 69.78 亿元（-6.00%），归母净利润 4.34 亿元（-29.61%），扣非净利润 3.70 亿元（-38.98%）。25Q3，营业收入 21.88 亿元（-2.20%），归母净利润 0.49 亿元（-63.39%），扣非净利润 0.38 亿元（- 71.77%）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 10,021 | 9,660 | 10,651 | 11,733 | | 同比增速(%) | 0.1% | -3.6% | 10.3% | 10.2% | | 归母净利润(百万) | 692 | 702 | 817 | 904 | | 同比增速(%) | 5.8% | 1.5% | 16.3% | 10.7% | | 每股盈利(元) | 1.14 | 1.16 | 1.35 | 1.49 | | 市盈率(倍) | 13 | 13 | 11 ...

公司研究 证 券 研 究 报 告 Q3 业绩加速上行，发布新一轮员工激励计划 目标价：57 元 事项： 公司发布 25 年三季报，25Q1-3，营业收入 4.48 亿元（+40.47%），归母净利润 1.36 亿元（+40.03%），扣非净利润 1.33 亿元（+49.53%）。25Q3，营业收入 1.82 亿元（+85.26%），归母净利润 0.62 亿元(+130.72%)，扣非净利润 0.61 亿元( +148.40%)。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 443 | 601 | 721 | 848 | | 同比增速(%) | -5.9% | 35.8% | 19.9% | 17.7% | | 归母净利润(百万) | 136 | 184 | 228 | 280 | | 同比增速(%) | -7.1% | 36.1% | 23.5% | 23.2% | | 每股盈利(元) | 1.13 | 1.54 | 1.9 ...